Based on the Immunovant Inc stock forecast from 11 analysts, the average analyst target price for Immunovant Inc is USD 48.61 over the next 12 months. Immunovant Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Immunovant Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Immunovant Inc’s stock price was USD 25.86. Immunovant Inc’s stock price has changed by -1.60% over the past week, -3.76% over the past month and -37.66% over the last year.
No recent analyst target price found for Immunovant Inc
No recent average analyst rating found for Immunovant Inc
Company Overview Immunovant Inc
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. Read Less
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatm...Read More
Frequently Asked Questions About Immunovant Inc (IMVT) Stock
Based on ratings from 11 analysts Immunovant Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 18 buy, sell and hold ratings.
Unfortunately we do not have enough data on IMVT's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for IMVT is USD 48.61 over the next 12 months. The maximum analyst target price is USD 60 while the minimum anlayst target price is USD 36.
Unfortunately we do not have enough data on IMVT's stock to indicate if its overvalued.
The last closing price of IMVT's stock was USD 25.86.
The most recent market capitalization for IMVT is USD 3.86B.
Based on targets from 11 analysts, the average taret price for IMVT is projected at USD 48.61 over the next 12 months.
This means that IMVT's stock price may go up by +87.98% over the next 12 months.
We can't find any ETFs which contains Immunovant Inc's stock.
As per our most recent records Immunovant Inc has 207 Employees.
Immunovant Inc's registered address is 320 West 37th Street, New York, NY, United States, 10018.
You can get more information about it from Immunovant Inc's website at https://immunovant.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Immunovant Inc (IMVT) Stock
Based on ratings from 11 analysts Immunovant Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 18 buy, sell and hold ratings.
Unfortunately we do not have enough data on IMVT's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for IMVT is USD 48.61 over the next 12 months. The maximum analyst target price is USD 60 while the minimum anlayst target price is USD 36.
Unfortunately we do not have enough data on IMVT's stock to indicate if its overvalued.
The last closing price of IMVT's stock was USD 25.86.
The most recent market capitalization for IMVT is USD 3.86B.
Based on targets from 11 analysts, the average taret price for IMVT is projected at USD 48.61 over the next 12 months.
This means that IMVT's stock price may go up by +87.98% over the next 12 months.
We can't find any ETFs which contains Immunovant Inc's stock.
As per our most recent records Immunovant Inc has 207 Employees.
Immunovant Inc's registered address is 320 West 37th Street, New York, NY, United States, 10018.
You can get more information about it from Immunovant Inc's website at https://immunovant.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IMVT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
